Cellectar Biosciences Announces Results of In Vivo Study Demonstrating PDC Platform Delivery of Paclitaxel to be Superior in Tumor Targeting to Free Paclitaxel Jun 15, 2016
Cellectar Biosciences Announces USPTO Issues Patent for its Radiotherapeutic PDC Portfolio, Further Strengthening and Expanding Protection for Its Delivery Platform May 31, 2016
Cellectar Biosciences Announces USPTO Issues Patent for New Phospholipid Drug Conjugate (PDC) with Paclitaxel May 25, 2016
Cellectar Biosciences to Present at the 5th Annual SeeThru Equity Microcap Investor Conference May 24, 2016
Cellectar Biosciences Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO May 20, 2016
Cellectar Biosciences to Host Conference Call on May 12, 2016 to Report First Quarter 2016 Financial Results and Provide a Corporate Performance Update May 4, 2016